Omnicell (NASDAQ:OMCL) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS

Omnicell (NASDAQ:OMCL) issued its quarterly earnings data on Thursday. The company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.16, Briefing.com reports. The business had revenue of $307.85 million for the quarter, compared to analyst estimates of $304.44 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%. Omnicell’s quarterly revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.

Here are the key takeaways from Omnicell’s conference call:

• Third-quarter results exceeded guidance, with revenue of $308 million and non-GAAP EBITDA of $45 million, supported by favorable product mix, gross margins, disciplined spending, and cost efficiencies.
• Omnicell raised full-year 2026 non-GAAP EBITDA guidance to $187 million–$193 million and EPS guidance to $2.48–$2.56, while narrowing revenue and ARR ranges because of improved visibility.
• The company said the Titan XT and OmniSphere pipeline grew modestly and became more mature, with Titan XT shipments beginning shortly and OmniSphere general availability still targeted for the first half of 2027. Management views OmniSphere subscriptions as a potentially high-margin, incremental revenue stream over time.
• Product bookings remain heavily back-end weighted, and management cited the timing of medium and large health-system decisions, competitive deal outcomes, and lengthy implementation cycles as sources of quarter-to-quarter variability.
• Second-half memory and component costs are expected to reduce margins by roughly $6 million, with about half incurred in the third quarter and the remainder expected in the fourth quarter; policy changes surrounding the 340B program are also expected to have a modest impact on 2026 ARR.

Omnicell Stock Performance

Shares of OMCL stock remained flat at $36.88 during mid-day trading on Friday. 230,978 shares of the stock were exchanged, compared to its average volume of 639,784. The firm’s 50 day moving average price is $34.58 and its 200 day moving average price is $39.19. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of 43.91, a PEG ratio of 0.90 and a beta of 0.98. Omnicell has a 12-month low of $31.75 and a 12-month high of $55.00.

Key Omnicell News

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Adjusted earnings beat estimates for the sixth consecutive quarter. Omnicell reported adjusted EPS of $0.58, versus the $0.42 analyst consensus and $0.51 a year earlier. Revenue of $307.9 million also modestly exceeded the $304.4 million estimate. Improved service margins were identified as a key earnings driver. Omnicell Q3 2026 earnings: Service margins power a sixth straight earnings beat
• Positive Sentiment: Profitability and cash generation improved. GAAP net income rose to $11.0 million, or $0.24 per diluted share, from $5.5 million, or $0.12 per share, in the prior-year quarter. Omnicell ended September with $314.9 million in cash and cash equivalents. Omnicell reports third-quarter revenue and GAAP net income
• Neutral Sentiment: Full-year guidance was updated. Management now expects 2026 revenue of $1.225 billion to $1.231 billion, non-GAAP EBITDA of $187 million to $193 million, and non-GAAP EPS of $2.48 to $2.56. The outlook suggests continued earnings discipline, but does not point to strong top-line growth. Omnicell provides fourth-quarter and full-year guidance
• Negative Sentiment: Revenue declined year over year and fourth-quarter guidance disappointed. Third-quarter revenue fell about 1% to $307.9 million, with product revenue declining to $173.1 million while service revenue increased slightly to $134.8 million. Fourth-quarter revenue guidance of $295 million to $301 million reportedly came in below expectations, raising concerns about near-term demand and growth. Omnicell exceeds third-quarter expectations but quarterly revenue guidance misses
• Negative Sentiment: Reported insider activity was entirely selling. Quiver Quantitative cited open-market sales by CEO Randall Lipps and other executives during the past six months, a signal that may weigh modestly on sentiment, although insider transactions do not necessarily indicate business deterioration. Omnicell financial results and trading activity

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. Wells Fargo & Company lowered their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. KeyCorp restated an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Piper Sandler restated an “overweight” rating and issued a $45.00 price objective (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Finally, Zacks Research upgraded shares of Omnicell from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $57.86.

About Omnicell

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.